RGLS

Regulus Therapeutics Inc.

2.02 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Regulus Therapeutics Inc. stock is down -11.01% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 58.33% of the previous 11 May’s closed higher than April. In the last 2 Unusual Options Trades, there were 2 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
23 May 14:29 16 Aug, 2024 1.00 CALL 250 60
24 May 14:30 16 Aug, 2024 1.00 CALL 270 433

About Regulus Therapeutics Inc.

Regulus Therapeutics Inc. engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies.

  • HC Wainwright & Co.
    Fri May 10, 07:49
    buy
    confirm
  • HC Wainwright & Co.
    Mon May 6, 14:00
    buy
    confirm